753 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Whalen Wealth Management Inc.

Whalen Wealth Management Inc. bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 753 shares of the biopharmaceutical company’s stock, valued at approximately $423,000.

A number of other large investors have also recently made changes to their positions in the stock. Marino Stram & Associates LLC lifted its holdings in Regeneron Pharmaceuticals by 5.3% during the 2nd quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 20 shares in the last quarter. Activest Wealth Management boosted its position in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 21 shares during the period. CX Institutional grew its stake in Regeneron Pharmaceuticals by 7.9% during the second quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 22 shares in the last quarter. Redwood Wealth Management Group LLC increased its position in shares of Regeneron Pharmaceuticals by 4.8% in the second quarter. Redwood Wealth Management Group LLC now owns 506 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 23 shares during the last quarter. Finally, Princeton Capital Management LLC raised its position in shares of Regeneron Pharmaceuticals by 1.9% during the 2nd quarter. Princeton Capital Management LLC now owns 1,240 shares of the biopharmaceutical company’s stock valued at $651,000 after buying an additional 23 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 7.02% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on REGN shares. Truist Financial began coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They issued a “buy” rating and a $798.00 price objective for the company. Hsbc Global Res upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. HSBC started coverage on Regeneron Pharmaceuticals in a research report on Monday, November 24th. They set a “buy” rating and a $255.00 price target on the stock. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, November 17th. Finally, Cantor Fitzgerald boosted their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $779.45.

Regeneron Pharmaceuticals Trading Down 0.1%

Regeneron Pharmaceuticals stock opened at $748.71 on Friday. The company has a market capitalization of $78.69 billion, a price-to-earnings ratio of 17.93, a price-to-earnings-growth ratio of 2.15 and a beta of 0.37. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $790.98. The business’s fifty day simple moving average is $678.34 and its two-hundred day simple moving average is $597.71.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the prior year, the firm posted $12.46 earnings per share. The business’s revenue was up .9% on a year-over-year basis. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were given a $0.88 dividend. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.